Vanda Pharmaceuticals is buy-rated following FDA approval of Nereus for motion sickness, with shares offering upside into 2026 catalysts. VNDA's Q3 saw strong Fanapt sales growth, but higher R&D and SG&A drove a $22.6M net loss, reflecting a strategic investment phase. The company maintains a robust $293.8M cash position, is guiding to $210–230M in 2025 revenue, and has ample runway to fund multiple late-stage launches.

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares are trading higher Wednesday after the company announced it received FDA approval of NEREUS for the prevention of vomiting induced by motion.

Vanda Pharma (VNDA) has reached multi-year highs following the FDA's approval of NEREUS, a treatment for motion-induced vomiting. This approval marks a signific

Vanda Pharmaceuticals (VNDA) jumped roughly 21% in premarket trading after the U.S. Food and Drug Administration approved its motion sickness therapy Nereus, al

The FDA approved Vanda's drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.

Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism.

Stock futures are in red early morning on New Year's Eve, after markets ended lower on Tuesday, as hopes of Santa Claus rally begin to fade.

Stock futures down, ORIS to acquire controlling stake in tea company, VNDA gets FDA approval, ELLO posts strong earnings.

Vanda Pharmaceuticals said on Tuesday its drug for the prevention of motion-induced vomiting was approved by the U.S. health regulator, becoming the first treatment for the condition to receive the nod in more than 40 years.

WASHINGTON, Dec. 30, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion. This approval marks the first new pharmacologic treatment in motion sickness in over four decades, representing a significant advancement in the understanding and management of this debilitating physiologic response that affects a substantial portion of the population and has long been recognized as a factor affecting military operational readiness.